Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
Medical device cybersecurity could be challenged by HHS staffing cuts
Democrats protested during a House Energy and Commerce subcommittee hearing on medical device safety, citing Health and Human Services (HHS) staffing cuts as a cybersecurity
